AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02209597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion XL 300
Description: Subjects will be studied in 4 phases for a total of approximately 28 weeks:~Phase 1: an approximately 4-week lead-in phase during which participants remain on their existing bupropion product Phases 2 - 4: randomized cross-over phases of approximately 6 weeks on each of the four bupropion study drugs (brand and 3 generics).
Study NCT04176822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational animated movie group
Description: Watching educational animation movie which were designed by the researcher before operation for fear and pain.
Study NCT04176822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Documentary movie group
Description: Watching documentary movie about trees before operation for fear and pain.
Study NCT01720602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO
Study NCT01720602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT01720602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: F-18 16 alpha-fluoroestradiol
Description: Correlative studies
Study NCT01720602 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies
Study NCT01720602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05004168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day Gel-0120
Description: Two milligrams of test article applied to the test area. The test products are Day Gel-0120C and Day Gel-0120-D. The products are applied together on the test area with
Study NCT05004168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P5 Reference Standard (SPF 35 reference)
Description: The reference product is P5 according to ISO 24444:2019. The application of reference product is similar with test product.
Study NCT02849223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal Transcranial Direct Current Stimulation
Description: 2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
Study NCT02849223 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: 30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
Study NCT01732523 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast enhanced carotid ultrasound
Study NCT02370693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
Study NCT02370693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 24 weeks
Study NCT02370693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
Study NCT04038775 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volunteering
Description: Subjects recommended volunteer by their provider.
Study NCT05113524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dance
Description: The dance program consists of 3 months of dance classes. Classes are specifically designed for people with Parkisnon's and lead by a qualified dance instructor experienced in teaching this population. The in-person dance classes are conducted in an appropriate room with chairs and ballet barres once a week. In addition, the participants received a CD containing a video of the recorded dance routine to be performed at home once a week. The class typically included a warm-up (10-15 min.), barre ballet exercises (10-15 min.), general dance-related activities (15-20 min), and a cool-down (10-15 min).
Study NCT05113524 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: Controls, not alter their personal lifestyle, but will undergo the same testing as the exercise intervention group.
Study NCT00749099 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pancrelipase
Description: The test drug (PANCRECARB® \[pancrelipase\] - Phase II) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
Study NCT00749099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.~Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each).
Study NCT01972477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1449
Description: Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
Study NCT02370693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Mycophenolate mofetil 1.5 g twice a day orally for 24 weeks
Study NCT00747071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colostrum
Description: Daily administration of Colostrum derived antibodies against C. difficile.
Study NCT01044693 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT01044693 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Description: Nebivolol 5mg single oral dose
Study NCT01044693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol tartrate 50 mg
Description: metoprolol tartrate 50 mg single oral dose
Study NCT01923389 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
Study NCT01044693 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil25 mg
Description: Sildenafil 25 mg single oral dose
Study NCT03460964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adhesive glucose sensor
Description: Will assess sensor's performance by comparing readings from an adhesive glucose sensor with those from a glucometer.~pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat
Study NCT03460964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Description: Pilocarpine 0.1 mL gel, applied to the skin via the glucose sensor to induce sweat; will apply a minimum of 2 doses to each participant.
Study NCT02609451 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileostomy closure
Description: Ileostomy closure at a different time point
Study NCT01972477 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given every day for 8 weeks.
Study NCT02940665 — intervention group
Intervention type: OTHER
Intervention: ERAS
Description: Patients in the ERAS group received the ERAS protocol
Study NCT00471471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide vaccine
Description: Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
Study NCT00471471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
Study NCT03158779 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT and chemotherapy
Description: Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction chemotherapy :~Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)~+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: Induction chemotherapy :~Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)~+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)~Bone marrow aspirate on D15 : if medullary blasts rate \< 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L).
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HD Cytarabine
Description: Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HD Cytarabine
Description: Consolidation chemotherapy course (s) :~-High dose cytarabine: 3g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: GvHD prophylaxis post allogeneic SCT :~-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: GvHD prophylaxis post allogeneic SCT :~-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Description: GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolic acid (MPA)
Description: GvHD prophylaxis post allogeneic SCT :~* 720 mg BID from D0 to D+28 for HLA-identical siblings~* 720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vosaroxin
Description: Consolidation chemotherapy course (s) :~-70 mg/m² on D1 and D4
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ID cytarabine
Description: Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group
Study NCT00471471 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF3512676
Description: 0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
Study NCT03741439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment
Description: Low intensity shockwave treatment in patients with mild/moderate ED using a electromagnetic emitter
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ID cytarabine
Description: Consolidation chemotherapy course (s) :~-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5~For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)~Up to 3 consolidation courses, depending on the patient AML risk group
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Consolidation chemotherapy course (s) :~-10 mg/12h on D1, D3 and D5
Study NCT02416388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Consolidation chemotherapy course (s) :~Once RP2D has been determined from the results of the dose selection phase (phase 1), the optimal dose level retained for randomized phase 2 will be one of the following:~* 100 mg/d on D1 to D8 (selection phase dose level 1)~* or 200 mg/d on D1 to D8 (selection phase dose level 2)~* or 400 mg/d on D1 to D8 (selection phase dose level 3)~* or 400 mg/d on D1 to D14 (selection phase dose level 4)
Study NCT03741439 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment
Study NCT03426215 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Changes in size and severity of the main herniated disc causing radiating pain will be evaluated by radiology specialists and Korean medicine doctors (KMDs) and categorized into three groups (improved, worse or no discernible change) in comparison with the immediate previous MRI to track long-term changes and assess for correlations in subjective clinical symptoms and objective physical evaluation and MRI results.
Study NCT01864577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative Pleural Suction at -20 cm H2O
Study NCT01864577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water seal
Study NCT04007874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinylestradiol/levonorgestrel
Description: Ethinylestradiol/levonorgestrel 30/150 µg oral tablets once daily without a stopweek for 3 months
Study NCT04007874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Vitamin E 400 IU oral capsules once daily for 3 months
Study NCT01310114 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Placenta-Derived Cells PDA001- (cenplacel-L)
Description: 240 mL of intravenous infusion
Study NCT01310114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Thawed placebo
Study NCT01864577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Water seal
Study NCT03109951 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Colonoscopy preparation using polyethylene glycol
Description: Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
Study NCT01496261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel and Aspirin
Description: Clopidogrel and Aspirin seperate combination, single dose
Study NCT01496261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination of clopidogrel/aspirin
Description: Fixed dose combination of clopidogrel/aspirin
Study NCT01568229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 747
Description: Three dose levels once-daily oral administration
Study NCT04135625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated nutrition and agricultural (INA) trainings
Description: Monthly INA training session to help increase knowledge about nutrition and chicken husbandry and help to increase resiliency on a household level.
Study NCT04135625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ceremonial Gifting of Livestock
Description: Egg laying chickens will be presented as a gift to the child by a community champion (their religious leader or village chief)) during a gifting ceremony
Study NCT01993355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
Study NCT01993355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
Study NCT01993355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
Study NCT01993355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
Study NCT02163330 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Study NCT02163330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Study NCT01568229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily oral administration
Study NCT01048515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine capsule 6 mg/kg given 1 hour before test
Study NCT01048515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: Caffeine capsule 6 mg/kg given 1 hour before test
Study NCT01718314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Misoprostol
Study NCT01718314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine pump spray
Study NCT01718314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Misoprostol)
Description: Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
Study NCT01718314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for Lidocaine)
Description: The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
Study NCT02858388 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinuclean Nebules 45
Description: Nebulization of solution
Study NCT02858388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Nebulization of solution
Study NCT04596657 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Description: Daily vitamin D3 supplementation (5000 IU)
Study NCT00719810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delafloxacin
Description: 300 mg intravenous every 12 hours
Study NCT00719810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: delafloxacin
Description: 450 mg intravenous every 12 hours
Study NCT00719810 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tigecycline
Description: 100 mg then 50 mg intravenous tigecycline every 12 hours
Study NCT02536482 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amix
Description: Treat the children with cow's milk allergy for 5 months.
Study NCT03517722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo matching to ustekinumab IV or SC.
Study NCT03517722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab (approximately 6 mg/kg)
Description: Participants will receive ustekinumab approximately 6 mg/kg via IV route based on body weight-range.
Study NCT03517722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants will receive 90 mg ustekinumab via SC route.
Study NCT00450463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF, Leukine)
Description: A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant deoxyribonucleic acid (DNA) technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
Study NCT00450463 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide (Eulexin)
Description: Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
Study NCT00450463 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide (Eulexin)
Description: Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
Study NCT00450463 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F/ TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.